Abstract
For ages aspirin has established its value as an analgesic, anti-inflammatory drug, but in 1938, it was found to be a causative factor of gastric inflammation (ulcer). Later discovered non-steroidal anti-inflammatory drugs (NSAIDs) were found effective as aspirin but failed to overcome the goal of safer aspirin. As the method of prostaglandin inhibition through COX is a common mechanism to both the wanted and unwanted effects of aspirin and non-aspirin NSAIDs, the COX enzyme becomes a target for drug designers for the development of the “safe aspirin”. In the late 1990s, a new class of drug molecules collectively known as selective inhibitors of cyclooxygenase-2(Coxibs) was developed for the treatment of pain and inflammation. Coxibs developed were as efficacious as the common NSAIDs, but they are devoid of major side effect, the gastrointestinal bleeding. This review presents an overview on all the discovered COX-2 inhibitors, their physiological role, side effects and reasons of their withdrawal.
Keywords: Coxib, cyclooxygenase, gastric bleeding, prostaglandin.
Current Drug Discovery Technologies
Title:Selective Cyclooxygenase Inhibitors: Current Status
Volume: 11 Issue: 2
Author(s): Ravindran Nandakishore, Prasanna R. Yalavarthi, Yengala R. Kiran and Malepati Rajapranathi
Affiliation:
Keywords: Coxib, cyclooxygenase, gastric bleeding, prostaglandin.
Abstract: For ages aspirin has established its value as an analgesic, anti-inflammatory drug, but in 1938, it was found to be a causative factor of gastric inflammation (ulcer). Later discovered non-steroidal anti-inflammatory drugs (NSAIDs) were found effective as aspirin but failed to overcome the goal of safer aspirin. As the method of prostaglandin inhibition through COX is a common mechanism to both the wanted and unwanted effects of aspirin and non-aspirin NSAIDs, the COX enzyme becomes a target for drug designers for the development of the “safe aspirin”. In the late 1990s, a new class of drug molecules collectively known as selective inhibitors of cyclooxygenase-2(Coxibs) was developed for the treatment of pain and inflammation. Coxibs developed were as efficacious as the common NSAIDs, but they are devoid of major side effect, the gastrointestinal bleeding. This review presents an overview on all the discovered COX-2 inhibitors, their physiological role, side effects and reasons of their withdrawal.
Export Options
About this article
Cite this article as:
Nandakishore Ravindran, Yalavarthi R. Prasanna, Kiran R. Yengala and Rajapranathi Malepati, Selective Cyclooxygenase Inhibitors: Current Status, Current Drug Discovery Technologies 2014; 11 (2) . https://dx.doi.org/10.2174/1570163811666140127123717
DOI https://dx.doi.org/10.2174/1570163811666140127123717 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Patent Selections
Recent Patents on Cardiovascular Drug Discovery The Changing Landscape of Voltage-Gated Calcium Channels in Neurovascular Disorders and in Neurodegenerative Diseases
Current Neuropharmacology Chemically Nano-Engineered Theranostics for Phytoconstituents as Healthcare Application
Current Biochemical Engineering (Discontinued) Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction
Current Pharmaceutical Design Synthetic Cannabinoids as Drugs of Abuse
Current Drug Abuse Reviews Pharmacology and Literature Review Based on Related Death and Non-Fatal Case Reports of the Benzofurans and Benzodifurans Designer Drugs
Current Pharmaceutical Design Fetal and Obstetric Manifestations in the Antiphospholipid Syndrome
Current Rheumatology Reviews Editorial [Hot Topic: Phosphodiesterase 5 Inhibitors: Pharmacology and Therapeutic Perspectives (Executive Editor: Giuseppe Barbaro)]
Current Pharmaceutical Design Iodine Prophylaxis in the Lights of the Last Recommendation of WHO on Reduction of Daily Salt Intake
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery An Update on Disease Modifying Antirheumatic Drugs
Inflammation & Allergy - Drug Targets (Discontinued) Novel Anti-Inflammatory Agents in COPD: Targeting Lung and Systemic Inflammation
Current Drug Targets An Insight Into the Anxiolytic Effects of Lignans (Phyllanthin and Hypophyllanthin) and Tannin (Corilagin) Rich Extracts of <i>Phyllanthus amarus</i> : An <i>In-Silico</i> and <i>In-vivo</i> approaches
Combinatorial Chemistry & High Throughput Screening Vascular Protection to Increase the Safety of Tissue Plasminogen Activator for Stroke
Current Pharmaceutical Design Pharmacogenomics in Psychiatry: Implications for Practice
Recent Patents on Biotechnology Management of Hypertension in Patients with Chronic Kidney Disease in Asia
Current Hypertension Reviews Resistin: A Promising Therapeutic Target for the Management of Type 2 Diabetes Mellitus?
Drug Design Reviews - Online (Discontinued) Gut Microbiota: A New Marker of Cardiovascular Disease
Current Pharmaceutical Design Aortic Dissection: A Review of the Pathophysiology, Management and Prospective Advances
Current Cardiology Reviews Calcium Channel Blockers in Obesity-Related Hypertension
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Uric Acid Metabolism in Pre-hypertension and the Metabolic Syndrome
Current Vascular Pharmacology